Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
Phase 2
90
about 5.3 years
21–70
1 site in MD
What this study is about
This trial is testing whether psilocybin can help people with opioid use disorder (OUD) stay sober and improve their lives when used alongside buprenorphine treatment. Participants will receive either a high dose or a low dose of psilocybin as an addition to standard outpatient buprenorphine care, and it will last for 1939 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Psilocybin
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
oral
Secondary: Depression as assessed by the Beck Depression Inventory II (BDII), Quality of Life as assessed by the World Health Organization Quality of Life Brief Version (WHOQOL-BREF)
Psychiatry / Mental Health